Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

576 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the need for a blood transfusion during surgery and to evaluate the levels of certain proteins in the blood when given tranexamic acid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

NCT01683955

Acute Blood Loss Anemia Osteoarthritis, Hip

COMPLETED PHASE1

The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery

NCT02684851

Acetabular Fractures

COMPLETED PHASE3

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

NCT03182751

Hip Fractures Intertrochanteric Fractures

COMPLETED PHASE2

Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy

NCT02253810

Dysplasia, Congenital Hip

COMPLETED NA

Tranexamic Acid in Hip Fracture Surgery

NCT02736383

Hip Fracture

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A review of the medical record between January 01 2013 to July 1st 2015 will be used to determine if the hypothesis that patients receiving tranexamic acid will have a lower need for blood transfusion and there are changes in the levels of the proteins essential for healthy oxygen transport throughout the body is correct. Tranexamic acid is a medication which may help wounds to stop bleeding more quickly. Participants are not expected to receive any direct benefits from participating in this study. Only a small risk of private patient medical information being exposed is anticipated. The results of this study will help surgeons and the medical community to better understand the uses of this type of drug and its possible role in benefiting hip replacement patients during and following surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tranexamic Acid Use Blood Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients 18 years of age and older
* Surgical patients who underwent primary total hip arthroplasty (THA)
* Surgical patients who underwent revision THA
* Preoperative hemoglobin values (N) 11 g/dl
* Normal international normalized ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT) values

Exclusion Criteria

* \- Allergy to tranexamic acid
* Bilateral THA
* History of ischemic heart disease
* Severe chronic heart failure
* Hepatic dysfunction
* Chronic renal failure
* On hemodialysis
* Cerebral infarction
* History of seizure
* Bleeding disorder
* Anticoagulant or aspirin-like medication and long acting NSAID medication
* Short acting NSAID's were discontinued at least 24 hrs before surgery

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No